TransMedics: Waiting On 2027 Catalysts (Rating Upgrade)

TransMedics' liver growth is moderating, increasing the company's dependence on international markets and heart, lung, and kidney to sustain growth. Heart and lung trial delays have created uncertainty, but successful completion in 12–18 months could reignite momentum. The long-term opportunity remains substantial, particularly OCS Kidney, but execution across new indications and Europe is increasingly critical to supporting TransMedics' valuation.

Seeking Alpha • Sep 18, 2026

2 Stocks Down 28% and 34% to Buy and Hold

TransMedics Group's investments are currently lowering margins, but they could eventually boost revenue and profits. SoFi Technologies is facing some near-term uncertainty, but the company's long-term prospects remain attractive.

The Motley Fool • Sep 15, 2026

TransMedics Group, Inc. (TMDX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

TransMedics Group, Inc. (TMDX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 14, 2026

TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into TransMedics Group, Inc. (NasdaqGM: TMDX) (“TransMedics” or the “Company”).TransMedics is a medical technology company focused on transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure. The Company operates the Organ Care System, or.

Business Wire • Sep 14, 2026

TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook

ANDOVER, Mass., Sept. 10, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), the global leader in portable warm perfusion for donor organs for transplantation, today announced the appointment of Fernando Araujo as Chief Financial Officer, effective September 21, 2026.

PRNewsWire • Sep 10, 2026

Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

PRNewsWire • Sep 7, 2026

Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?

TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Sep 3, 2026

Is TMDX Stock Worth Buying as Growth Meets Rising Margin Pressure?

TransMedics' rapid revenue growth and cheaper valuation face rising margin pressure as heavy investment raises execution risks.

Zacks Investment Research • Sep 3, 2026

TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDX

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX).

GlobeNewsWire • Sep 3, 2026

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX

NEW YORK, Aug. 31, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). If you currently own shares of TransMedics Group stock, please visit the firm's website at https://rosenlegal.com/cases/transmedics-group-inc/join for more information.

PRNewsWire • Sep 1, 2026